Abstract: The present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a CTLA4 peptide-immunoglobulin fusion, preferably LEA29Y, and expresses said CTLA4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets.
Type:
Grant
Filed:
October 27, 2016
Date of Patent:
May 14, 2019
Assignee:
MWM BIOMODELS GMBH
Inventors:
Eckhard Wolf, Nikolai Klymiuk, Lelia Wolf-Van Buerck, Jochen Seißler
Abstract: The present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a CTLA4 peptide-immunoglobulin fusion, preferably LEA29Y, and expresses said CTLA4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets.
Type:
Application
Filed:
October 24, 2012
Publication date:
April 24, 2014
Applicant:
MWM Biomodels GmbH
Inventors:
Eckhard Wolf, Nikolai Klymiuk, Lelia Wolf-van Buerck, Jochen Seissler
Abstract: The present invention relates to transgenic pigs containing a dominant-negative incretin hormone receptor, namely the dominant-negative human glucose-dependent insulinotropic polypeptide receptor. The present invention furthermore relates to uses of these transgenic pigs as clinically relevant animal model systems for studying the pathogenesis and novel therapies for diabetes mellitus type 2, particularly for the maintenance and expansion of pancreatic ?-cell mass.
© 2025 Justia
